These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21286272)

  • 21. Analysis of drug coverage before and after the implementation of Canada's Common Drug Review.
    Gamble JM; Weir DL; Johnson JA; Eurich DT
    CMAJ; 2011 Nov; 183(17):E1259-66. PubMed ID: 22025648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces.
    Morgan SG; Thomson PA; Daw JR; Friesen MK
    BMC Health Serv Res; 2013 Jan; 13():34. PubMed ID: 23363626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Not All Canadian Cancer Patients Are Equal-Disparities in Public Cancer Drug Funding across Canada.
    MacPhail C; Snow S
    Curr Oncol; 2022 Mar; 29(3):2064-2072. PubMed ID: 35323366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using economic evaluations to make formulary coverage decisions. So much for guidelines.
    Anis AH; Gagnon Y
    Pharmacoeconomics; 2000 Jul; 18(1):55-62. PubMed ID: 11010604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Need for an improved submission process for listing drugs for reimbursement in Canadian provinces.
    West R; Borden EK; Collet JP; Rawson NS; Tonks RS
    Can J Clin Pharmacol; 2003; 10(4):207-10. PubMed ID: 14712327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ontario's formulary committee: how recommendations are made.
    PausJenssen AM; Singer PA; Detsky AS
    Pharmacoeconomics; 2003; 21(4):285-94. PubMed ID: 12600223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Common Drug Review recommendations: an evidence base for expectations?
    Rocchi A; Miller E; Hopkins RB; Goeree R
    Pharmacoeconomics; 2012 Mar; 30(3):229-46. PubMed ID: 22283689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canadian status of "drugs to avoid" in 2017: a descriptive analysis.
    Lexchin J
    CMAJ Open; 2018; 6(3):E430-E435. PubMed ID: 30266781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A dog's breakfast: prescription drug coverage varies widely across Canada.
    Anis AH; Guh D; Wang Xh
    Med Care; 2001 Apr; 39(4):315-26. PubMed ID: 11329519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluations in the canadian common drug review.
    Laupacis A
    Pharmacoeconomics; 2006; 24(11):1157-62. PubMed ID: 17067199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Self-Monitoring of Blood Glucose: Impact of Quantity Limits in Public Drug Formularies on Provincial Costs Across Canada.
    Knowles SR; Lee K; Paterson JM; Shah BR; Mamdani MM; Juurlink DN; Gomes T
    Can J Diabetes; 2017 Apr; 41(2):138-142. PubMed ID: 27989494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of a three-tier formulary on antidepressant utilization and expenditures.
    Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
    J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment.
    Grootendorst P
    Can J Clin Pharmacol; 2002; 9(2):79-99. PubMed ID: 12172588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disparity in public funding of systemic therapy for metastatic renal cell carcinoma in Canada.
    Jackson EB; Hotte SJ
    Can Urol Assoc J; 2022 Nov; 16(11):E516-E522. PubMed ID: 35704937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost.
    Rawson NS
    Orphanet J Rare Dis; 2017 Mar; 12(1):59. PubMed ID: 28330479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of formulary policy decisions on antimicrobial drug utilization in British Columbia.
    Marra F; Patrick DM; White R; Ng H; Bowie WR; Hutchinson JM
    J Antimicrob Chemother; 2005 Jan; 55(1):95-101. PubMed ID: 15590717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What can the Canadians and Americans learn from each other's health care systems?
    Weil TP
    Int J Health Plann Manage; 2016 Jul; 31(3):349-70. PubMed ID: 27469581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The value and consequences of using public health technology assessments for private payer decision-making in Canada: one size does not fit all.
    Pericleous L; Amin M; Goeree R
    J Med Econ; 2019 May; 22(5):478-487. PubMed ID: 30757934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.